FSNUF - Fresenius: It's Darkest Before The Dawn
2024-05-07 07:30:00 ET
Summary
- Fresenius, a German healthcare company, has the potential for significant growth and a near-term turnaround.
- The company is in the midst of a restructuring and has met its revenue and earnings targets for 2023.
- Despite suspending its dividend, Fresenius is undervalued and has a compelling valuation, with an upside of over 20% per year. I view the company as a "BUY" here.
Dear subscribers,
It's been some time since I wrote an iREIT update on Fresenius ( FSNUY ), and the last time I covered the company was back in the middle of 2023. The company in question, for those of you who are not familiar with it at this time, is a German healthcare company, I highlight it as a promising investment due to its global presence, market leadership, and potential for significant growth in the coming years.
However, Fresenius has, for the longest time, lagged any market indicator and peer here that I would consider relevant. Despite potential upside and turnarounds, the company has continually failed to deliver on that reversion - until now, at least. There is the worry that the company's issues are systemic and that the best we can hope for is stabilization, as opposed to attractive returns....
Fresenius: It's Darkest Before The Dawn